Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today ...

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell ...

CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

Corn rootworms, pests responsible for billions of dollars in yearly crop losses, are evolving resistance that weakens even ...

The skyline above the Fontaine Research Park temporarily includes two cranes as construction continues on projects such as ...